Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-2: Vepugratinib + Enfortumab Vedotin + Pembrolizumab in FGFR3-altered Metastatic Urothelial Carcinoma
jRCT2051250160Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of vepugratinib in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab, Overall Response Rate (ORR) by Investigator Assessment (Safety Lead-In) and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
vepugratinib
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2051250160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250160.